Latest News
Evogene targets acute graft-versus-host disease for AI-driven drug discovery programme
28 October 2026 - Computational chemistry company Evogene Ltd (NASDAQ: EVGN) (TASE: EVGN) announced on Wednesday that it has selected acute graft-versus-host disease (aGVHD) as the target indication for its internal AI-driven drug discovery programme...
MetaVia announces presentation of DA-1726 Phase 1 data at Precision Liver Symposium
28 October 2026 - Biotechnology company MetaVia Inc (Nasdaq: MTVA) announced on Wednesday that it will present Phase 1 clinical trial data for DA-1726, its investigational dual GLP-1 and glucagon receptor agonist, at the Precision Liver Symposium 202...
Genmab reports 50% reduction in risk of death in Phase 3 head and neck cancer trial
28 October 2026 - Danish biotechnology company Genmab A/S (CPH:GMAB) on Wednesday announced positive topline results from its Phase 3 LiGeR-HN1 trial, showing that petosemtamab combined with pembrolizumab significantly improved overall survival and o...
United Therapeutics receives FDA clearance to advance inhaled PAH therapy into clinical trials
28 October 2026 - Biotechnology company United Therapeutics Corporation (Nasdaq:UTHR) announced on Wednesday that the US Food and Drug Administration (FDA) has cleared its Investigational New Drug application for Treprostinil-Iloprost SMI, enabling t...
Novocure and Verastem to evaluate combination therapy for pancreatic cancer
28 October 2026 - Global oncology company Novocure (Nasdaq:NVCR) said on Wednesday that it has entered into a clinical trial collaboration and supply agreement with biopharmaceutical company Verastem Oncology (Nasdaq:VSTM) to evaluate Tumor Treating ...